CLINICAL TRIALS PROFILE FOR GENOTROPIN
✉ Email this page to a colleague
All Clinical Trials for Genotropin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00119769 ↗ | The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients | Completed | Pfizer | Phase 4 | 2005-02-01 | The purpose of this study is to investigate the effect of low-dose human growth hormone therapy on immune status and fat morphology. |
| NCT00119769 ↗ | The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients | Completed | Hvidovre University Hospital | Phase 4 | 2005-02-01 | The purpose of this study is to investigate the effect of low-dose human growth hormone therapy on immune status and fat morphology. |
| NCT00136032 ↗ | Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women | Completed | Massachusetts General Hospital | N/A | 2002-01-01 | The purpose of the study is to evaluate the effects of growth hormone replacement on women with growth hormone deficiency. Growth hormone deficiency means the body no longer produces growth hormone due to a tumor or some kind of disease of the brain in an area called the pituitary/hypothalamic region. This is the area of the brain where growth hormone is normally produced. We, the researchers at Massachusetts General Hospital, will establish the effects of growth hormone replacement on cardiovascular parameters (laboratory tests, the flexibility of the arteries, changes in heart rate) in women with growth hormone deficiency. Our goal is to see if this therapy: - has effects on women's cardiovascular risk markers (special blood tests which indicate how healthy the heart and arteries are) - has effects on women's types and levels of various substances circulating in their blood - in women affects the stiffness of their arteries and heart rate variability in parallel with changes in cardiovascular risk markers - has different effects depending on whether women are pre or post menopausal. Participation in this study is expected to last approximately 12 months. |
| NCT00174408 ↗ | Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age | Completed | Pfizer | Phase 3 | 1990-03-01 | The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA. Safety of the drug is a main objective as well. The growth promoting effect of two different dosages is compared. The effect of long-term treatment on final height is evaluated (according to several amendments) |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Genotropin
Condition Name
Clinical Trial Locations for Genotropin
Trials by Country
Clinical Trial Progress for Genotropin
Clinical Trial Phase
Clinical Trial Sponsors for Genotropin
Sponsor Name
